The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer and better structured cooperation than before. Their common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realization of the above-mentioned project.

November 21, 2019: A symposium “New opportunities for reducing cardiovascular risk in the Russian Federation”, organized by EGIS-RUS, was held in the frame of the XIV National Congress of Therapists.

New Year is a time of miracles and cherished wishes, it is essentially about and for children. Therefore, EGIS-RUS decided to give them a charity Christmas Tree “Chain of Good”. On December 21, 2019, EGIS-RUS’ office opened its doors for the children of the employees and young guests from the orphanage in Moscow.

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.

From October 7 to December 22, 2019, there will be a TV broadcasting campaign in support of Sinuforte®. The commercial under the slogan “Do not let sinusitis cling on to you” is broadcasting on the largest federal television channels: Russia, TNT, Muz-TV, Friday, Channel 5, TV-3, Disney, U.